2,3-Dimethoxy-5-methyl-p-benzoquinone (Synonyms: Coenzyme Q0, CoQ0) |
| Catalog No.GC40947 |
La 2,3-diméthoxy-5-méthyl-p-benzoquinone (CoQ0) est un puissant composé d'ubiquinone actif oral qui peut être dérivé d'Antrodia cinnamomea.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 605-94-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
2,3-Dimethoxy-5-methyl-p-benzoquinone, also known as coenzyme Q0, is a key intermediate in the synthesis of coenzyme Q, coenzyme Q10, other ubiquinones, and vitamin E. It inhibits the growth of SKOV-3, A2780, and A2870/CP70 human ovarian carcinoma cells (IC50s = 26.6, 27.3, and 28.4 µM, respectively) with a cytotoxic concentration of greater than 40 µM for non-cancerous ovarian surface epithelial cells. It halts the cell cycle at the G2/M phase, increases the production of reactive oxygen species (ROS), and induces autophagy and apoptosis in SKOV-3 cells. 2,3-Dimethoxy-5-methyl-p-benzoquinone downregulates the protooncogene HER-2 and decreases the protein levels of phosphorylated AKT and mTOR in SKOV-3 cells. It also decreases the incidence of tumors and tumor burden in a SKOV-3 human ovarian carcinoma mouse xenograft model when administered at a dose of 2.5 mg/kg every four days.
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *